SAB Biotherapeutics Announces Results of 2026 Annual Meeting and Election of Directors

On June 18, 2026, SAB Biotherapeutics, Inc. held its 2026 Annual Meeting of Stockholders. During the meeting, shareholders voted on two primary proposals. First, stockholders approved the election of four Class II directors: Dr. David Zaccardelli, Pharm.D., Katie Ellias, David Link, MBA, and Andrew Moin. These directors will serve a three-year term ending at the 2029 Annual Meeting of Stockholders, or until their successors are qualified or they vacate their positions. Second, stockholders ratified the appointment of EisnerAmper LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. Approximately 76.12% of the outstanding shares entitled to vote were represented at the meeting, establishing a quorum. The voting results for the director elections showed strong support, with Dr. Zaccardelli and Ms. Ellias receiving over 48 million 'For' votes each. The ratification of the accounting firm passed with 59,319,363 votes in favor. No other business matters were reported in this filing.